Are GLP-1 receptor agonists (GLP-1 RAs) destined to become lifelong medications? This question has sparked intense debate, especially after a recent systematic review published in the BMJ (https://www.bmj.com/content/392/bmj-2025-085304) shed light on what happens when patients stop these treatments. But here’s where it gets controversial: while these drugs are effective for weight loss and managing cardiometabolic risks, the review found that both weight and health markers like blood pressure and blood sugar often rebound rapidly once treatment stops—sometimes faster than with other interventions. This raises a critical question: should we even start patients on these medications in the first place? Let’s dive into the evidence and expert opinions to unpack this complex issue.
The Rebound Effect: Predictable, Yet Troubling
Professor Clare Collins, a leading expert in nutrition and dietetics at the University of Newcastle, isn’t surprised by the rapid weight regain after stopping GLP-1 RAs. ‘This is exactly what you’d expect,’ she explains. After all, chronic conditions tend to return when their treatments are discontinued—just like blood pressure rises when antihypertensives are stopped. And this is the part most people miss: while weight regain grabs headlines, the more alarming issue is the deterioration in metabolic health markers, which can revert to pre-treatment levels. ‘This predictable rebound underscores the need for better long-term maintenance strategies,’ Prof. Collins emphasizes.
Not a Failure, But a Feature
Associate Professor Trevor Steward, Director of the Brain and Mental Health Hub at the Melbourne School of Psychological Sciences, clarifies that this rebound isn’t a sign of treatment failure. Instead, it reflects how GLP-1 RAs work. Unlike drugs that create permanent changes, these medications amplify existing hormonal signals in the body, particularly those regulating appetite, digestion, and satiety. Once the treatment stops, so does the hormonal boost, leading to rapid weight regain. However, the exact mechanisms behind this accelerated rebound remain unclear, with some evidence suggesting newer medications may cause a stronger ‘slingshot effect.’
The Role of the Brain and Environment
Emerging research suggests GLP-1 RAs may cross the blood-brain barrier, influencing reward pathways tied to appetite and food cravings. Prof. Collins uses the term ‘food noise’ to describe this—think of impulsively buying donuts alongside a loaf of bread. ‘These therapies can reduce that noise,’ she notes. But when treatment stops, the surrounding food environment can quickly regain its influence. This is where tapering, behavioral support, and nutrition strategies become crucial. ‘Patients may be more open to maintenance programs during tapering,’ she adds, ‘helping them recognize when food noise returns.’
Nutrition: The Overlooked Piece of the Puzzle
In a systematic review led by Prof. Collins (https://pubmed.ncbi.nlm.nih.gov/41491340/), she highlights a glaring gap: dietary intake and nutrition are rarely measured in incretin trials. ‘Only two out of all phase three trials tracked what participants ate,’ she reveals. While most trials offer standardized advice, they don’t collect data on how appetite suppression, nausea, or early satiety affect eating patterns. Reduced calorie intake doesn’t automatically mean better nutrition—micronutrient deficiencies and muscle loss can emerge if diet quality isn’t monitored.
Pharmacists, with their frequent patient interactions, are uniquely positioned to spot these issues early and refer patients to dietitians for medical nutrition therapy. Prof. Collins also points to resources like the University of Newcastle’s healthy eating quiz and obesity management podcast (https://nomoneynotime.com.au/) as valuable tools for patients.
The Long-Term Perspective
A/Prof. Steward argues that weight regain after stopping GLP-1 RAs should be normalized, especially given the risks of long-term obesity. For some patients, continued therapy may be the lower-risk option. ‘Clinicians are increasingly viewing these drugs as potentially lifelong treatments, similar to those for other chronic conditions,’ he says. However, he stresses the need for clearer evidence on tapering and maintenance, as clinicians currently ‘operate in the dark.’
Here’s a thought-provoking question: Should GLP-1 RAs be prescribed for non-health reasons, like preparing for a wedding? A/Prof. Steward warns against this, emphasizing that these are serious medications with systemic effects, not quick fixes for temporary weight loss. Prof. Collins adds that while the BMJ findings shouldn’t deter prescribing, the long-term costs must be contextualized, including potential savings from improved health.
The Future of GLP-1 RAs
With over half a million Australians now on these medications, clinical messaging must evolve alongside the evidence. Potential PBS listings and new formulations are on the horizon, but clinicians still need clearer guidance on long-term use. What do you think? Should GLP-1 RAs be considered lifelong treatments, or is there a better way to manage weight and metabolic health? Share your thoughts in the comments—let’s spark a conversation!
